Press Releases

December 10, 2019

ProMIS Neurosciences’ Alzheimer’s disease program takes on renewed significance following positive aducanumab news 

December 5, 2019

Aducanumab is good; next generation Alzheimer’s disease therapies will be better

November 18, 2019

ProMIS Neurosciences Completes First Closing of Private Placement

Press Archives

In the News

November 7, 2019

STAT – Biogen’s good news on aducanumab could ‘open the floodgates’ for Alzheimer’s drugs

November 7, 2019

Financial Times – Alzheimer’s drug revival gives hope to millions — and investors

June 13, 2019

The Big Biz Show – Interview with Dr. Elliot Goldstein

News Archives

Presentations

November 6, 2019

ProMIS Neurosciences: “Best in Class” therapy for misfolded protein diseases, based on a proprietary discovery platform

September 10, 2019

Executive Chairman Gene William’s Presentation at the HC Wainwright Investor Conference

August 12, 2019

CSO Neil Cashman’s overview of ProMIS’ unique capability to selectively target toxic, misfolded proteins that are root causes of neurodegenerative diseases

Presentations Archives

Videos

November 6, 2019

ProMIS Neurosciences: “Best in Class” therapy for misfolded protein diseases, based on a proprietary discovery platform

August 6, 2019

Dr. James Kupiec’s update from AAIC 2019: Demonstrating Early Proof-of-Concept with Biomarkers and Focused Patient Populations

July 18, 2019

ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019 

Video Archives